Lyell Immunopharma (LYEL) Asset Writedowns and Impairment (2021 - 2025)

Lyell Immunopharma has reported Asset Writedowns and Impairment for 4 years, with the latest figure at -$43000.0 in Q4 2025.

• Quarterly Asset Writedowns and Impairment fell 100.08% year-over-year to -$43000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52.7 million (up 13.73% YoY) and the FY2025 annual result came in at $1.4 million, down 97.27% from the prior year.
• Asset Writedowns and Impairment fell to -$43000.0 in Q4 2025 per LYEL's latest filing, from $1.4 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $51.3 million in Q4 2024 and troughed at -$5.0 million in Q4 2022.
• A 4-year average of $14.8 million and a median of $3.2 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2022 and 2025: Asset Writedowns and Impairment tumbled 113.74% in 2022, then plunged 100.08% in 2025.
• Over 4 years, Asset Writedowns and Impairment stood at $36.4 million in 2021, then sank by 113.74% to -$5.0 million in 2022, then soared by 1125.94% to $51.3 million in 2024, then tumbled by 100.08% to -$43000.0 in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$43000.0, $1.4 million, and $51.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.